0001654954-22-008910.txt : 20220628
0001654954-22-008910.hdr.sgml : 20220628
20220628163206
ACCESSION NUMBER: 0001654954-22-008910
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220624
FILED AS OF DATE: 20220628
DATE AS OF CHANGE: 20220628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILLS STEPHEN T
CENTRAL INDEX KEY: 0001103883
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15543
FILM NUMBER: 221050563
MAIL ADDRESS:
STREET 1: PALATIN TECHNOLOGIES, INC.
STREET 2: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC
CENTRAL INDEX KEY: 0000911216
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 954078884
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 609-495-2200
MAIL ADDRESS:
STREET 1: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: INTERFILM INC
DATE OF NAME CHANGE: 19930825
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2022-06-24
0000911216
PALATIN TECHNOLOGIES INC
PTN
0001103883
WILLS STEPHEN T
PALATIN TECHNOLOGIES, INC.
4B CEDAR BROOK DRIVE
CRANBURY
NJ
08512
false
true
false
false
Executive VP and CFO/COO
Common Stock
2022-06-24
4
A
false
40659
0
A
9360658
D
Stock Option (Right to Buy)
0.55
2022-06-24
4
A
false
497000
0
A
2025-06-22
2031-06-22
Common Stock
497000
497000
D
Stock Option (Right to Buy)
0.55
2022-06-24
4
A
false
186375
0
A
2025-06-22
2031-06-22
Common Stock
186375
186375
D
Restricted share units granted under the 2011 Stock Incentive Plan (the "Plan"), each of which represents the right to receive, without further payment, one share of common stock. On June 22, 2021, the Company granted performance-based restricted stock units to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.
Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted time-based options to its executive officers which vest at the rate of 25% per year, starting in June 2022, contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022
Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted performance-based options to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.
/s/ Stephen T. Wills by Stephen A. Slusher, Attorney-in-Fact
2022-06-28